First reported 17 hours ago -
Updated 17 hours ago -
By Charlotte BathJuly 25, 2014, Volume 5, Issue 12A multicenter, open-label phase II trial found that the selective proteasome inhibitor carfilzomib (Kyprolis), in combination with cyclophosphamide
and dexamethasone produced high complete response rates ...
[Published The ASCO Post - 17 hours ago]